Our Heritage is In Hematology

American Society of Hematology Annual Meeting 2019

Booth #2331

A Letter from Our CEO

10 years. That’s how long it’s been since Agios opened its labs with the promise to accelerate discovery in the field of cellular metabolism. Later that same year, Nature published the groundbreaking research from our scientists, which found that IDH mutations were driving the proliferation of a wide range of blood and solid tumor cancers. This discovery led to our first clinical trial in acute myeloid leukemia, and our next big scientific breakthrough led to the development of the first potential therapy for a rare hemolytic anemia called pyruvate kinase deficiency.

Our roots are in hematology, and at this year’s American Society of Hematology (ASH) Annual Meeting, we’re celebrating the great science that got us here, unveiling new findings that help us further understand the role that IDH mutations and PKR activation play in hematologic diseases, and learning from this tremendous community that shares our dedication to making a difference for patients.

We look forward to presenting new data across our pipeline in Orlando. Visit us at our booth and come learn more about our leadership in understanding IDH inhibition in cancer and PKR activation in hematolytic anemias. I also invite you to follow us on Twitter and LinkedIn and engage in the conversation using #HeritageinHeme.

 

Jackie Fouse, Ph.D.

Chief Executive Officer

For 10 years, we have pioneered the science behind IDH mutations in hematologic malignancies and PKR activation in rare hemolytic anemias.

Unlocking the
Promise of IDH
in Hematologic
Malignancies

Read More

Hematology
is at our Core

Read More

Activating PKR
in Rare Hemolytic
Anemias

Read More

ASH 2019 Data Room

View our latest news and presentations from the ASH Annual Meeting

Follow along with Agios at #ASH2019

Follow @agiospharma

Driven by the desire to push boundaries, we combined our knowledge of the metabolome and the genome to develop precision medicines for patients with cancers that harbor IDH mutations starting with acute myeloid leukemia.

X Close

Our research platform was built around our deep understanding of metabolic pathways and precision medicine with the vision to develop transformational medicines for patients who need them.

X Close

Leveraging our prolific scientific platform, we are building a pipeline of disease-modifying medicines designed to significantly slow, halt or reverse rare genetic metabolic diseases.

X Close